Biotech Daily Dose


bank-feb04.jpg Historically, biotech stocks have performed reasonably well in the month of January, and this year too, it has been no different. The iShares Nasdaq Biotechnology ETF (IBB) a bellwether of investor sentiment, has so far gained nearly 16%. Listed below are some of the biotech stocks that made triple-digit gains in January, and their near-term catalysts to watch out for.

pharmacalendar-feb01.jpg Here are some of the pharma/biotech stocks to watch out for in the week starting February 4.

pharma-021517_01feb19.jpg Today's Daily Dose brings you news about the delay in filing of AVEO Pharma's NDA for FOTIVDA for renal cell cancer; Corcept's lower-than-expected fourth quarter revenue; Edwards LifeSciences' strong profitability and 10 percent sales growth in Q4; suspension of OPKO Health's Benign Prostatic Hyperplasia trial; and FDA approval of first generic of Glaxo's ADVAIR DISKUS.

pharma-022217_30jan19.jpg Today's Daily Dose brings you news about wide acceptance of AVITA Medical's RECELL System for burns in the U.S.; FDA's "MRI safe" notice to Senseonics' Eversense; SCYNEXIS' positive phase III results in patients with refractory or intolerant fungal disease; and Surmodics' better-than-expected fiscal 2019 first quarter results and revised outlook.

todaynews-jan30.jpg Genentech, a member of the Roche Group (RHHBY.OB), has decided to discontinue its phase III clinical studies of Crenezumab in early Alzheimer's disease, dubbed CREAD 1 and CREAD 2, as the compound was unlikely to meet the primary endpoint.

pharma-022017_29jan19.jpg Neurocrine Biosciences Inc. (NBIX) and Voyager Therapeutics Inc. (VYGR) have formed a strategic development and commercialization collaboration for Parkinson's disease and Friedreich's Ataxia.

pharma-030218_28jan19.jpg OrganiGram Holdings Inc. (OGI.V), a licensed producer of cannabis, has reported encouraging results for the first quarter of fiscal 2019.

pharma-022317_23jan19.jpg Today's Daily Dose brings you news about stock offerings of Ohr Pharma, NuCana, UroGen; General Mills' recall of Gold Medal Unbleached Flour; partial clinical hold on Advaxis' cervical cancer trial; and Ironwood Pharma's progress with central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator IW-6463.

pharma-022018_23jan19.jpg Today's Daily Dose brings you news about Green Growth's unsolicited take-over bid for Aphria; the stock offering of Bellerophon, PTC Therapeutics; Accuray's better-than-expected Q2 results; UNITY Biotechnology's progress in osteoarthritis trial; positive data from Ultragenyx Pharma's phase II study of UX007 in patients with long-chain fatty acid oxidation disorder.

Follow RTT